Last Updated : April 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Orfadin | nitisinone | Hereditary tyrosinemia type 1 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Renflexis | infliximab | rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Akynzeo | netupitant / palonosetron | Nausea and vomiting (chemotherapy induced) prevention | Reimburse with clinical criteria and/or conditions | Complete | ||
| Tecentriq | Atezolizumab | Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Probuphine | buprenorphine hydrochloride | Opioid drug dependence, treatment | Reimburse with clinical criteria and/or conditions | Complete | ||
| Juluca | Dolutegravir rilpivirine | HIV infection | Reimburse with clinical criteria and/or conditions | Complete | ||
| Monoprost | latanoprost | glaucoma and ocular hypertension | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ocrevus | ocrelizumab | Primary progressive multiple sclerosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kanuma | sebelipase alfa | Lysosomal acid lipase deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
| Repatha | Evolocumab | Primary hyperlipidemia and mixed dyslipidemia | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 29, 2024